INTRODUCTION:Drug-eluting stents (DES) have significantly decreased the need for repeat coronary revascularization but concerns remain regarding the safety of first and second generation DES. We compared the safety and efficacy of a biolimus-eluting stent (with biodegradable polymer) with an everolimus-eluting stent (with durable polymer) one. METHODS: We performed a randomized trial to compare the two types of stents. Two hundred patients undergoing PCI for de novo lesions were randomly assigned 1:1 to treatment with either biolimus-eluting (BioMatrix) or everolimus -eluting (Xience V) stent. The primary endpoint was a composite of cardiac death, myocardial infarction, and clinically driven target vessel revascularization within 12 months. RESULTS:Demographics, clinical, and lesion characteristic were comparable between two groups. The 30-day major adverse car-diac event (MACE) rate was 2% in BioMatrix group versus 0% in Xience group (p > 0.05). After 12 months, the rates of cardiac death (0% in both groups), MI (2% versus 0%, p=0.49) and clinically -driven target vessel revascularization (0% in both groups) were similar for BioMatrix and Xience. No stent thrombosis was reported at 1, 6, 9 or 12 months after intervention in either group. CONCLUSION:BES (Biolimus-eluting stent) with biodegradable polymer and EES (Everolimus-eluting stent) with durable polymer appear similar with respect to MACE and stent thrombosis in this patient population. Many studies with longer follow up are needed to define better the role of BES with biodegradable polymer in treatment of coronary artery lesions.
RCT Entities:
INTRODUCTION: Drug-eluting stents (DES) have significantly decreased the need for repeat coronary revascularization but concerns remain regarding the safety of first and second generation DES. We compared the safety and efficacy of a biolimus-eluting stent (with biodegradable polymer) with an everolimus-eluting stent (with durable polymer) one. METHODS: We performed a randomized trial to compare the two types of stents. Two hundred patients undergoing PCI for de novo lesions were randomly assigned 1:1 to treatment with either biolimus-eluting (BioMatrix) or everolimus -eluting (Xience V) stent. The primary endpoint was a composite of cardiac death, myocardial infarction, and clinically driven target vessel revascularization within 12 months. RESULTS: Demographics, clinical, and lesion characteristic were comparable between two groups. The 30-day major adverse car-diac event (MACE) rate was 2% in BioMatrix group versus 0% in Xience group (p > 0.05). After 12 months, the rates of cardiac death (0% in both groups), MI (2% versus 0%, p=0.49) and clinically -driven target vessel revascularization (0% in both groups) were similar for BioMatrix and Xience. No stent thrombosis was reported at 1, 6, 9 or 12 months after intervention in either group. CONCLUSION:BES (Biolimus-eluting stent) with biodegradable polymer and EES (Everolimus-eluting stent) with durable polymer appear similar with respect to MACE and stent thrombosis in this patient population. Many studies with longer follow up are needed to define better the role of BES with biodegradable polymer in treatment of coronary artery lesions.
Authors: Scot Garg; Giovanna Sarno; Patrick W Serruys; Ton de Vries; Pawel Buszman; Axel Linke; Thomas Ischinger; Volker Klauss; Franz Eberli; Roberto Corti; William Wijns; Marie-Claude Morice; Carlo Di Mario; Robert Jan van Geuns; Pedro Eerdmans; Gerrit-Anne van Es; Bernhard Meier; Peter Jüni; Stephan Windecker Journal: EuroIntervention Date: 2010-06 Impact factor: 6.534
Authors: Stephan Windecker; Patrick W Serruys; Simon Wandel; Pawel Buszman; Stanislaw Trznadel; Axel Linke; Karsten Lenk; Thomas Ischinger; Volker Klauss; Franz Eberli; Roberto Corti; William Wijns; Marie-Claude Morice; Carlo di Mario; Simon Davies; Robert-Jan van Geuns; Pedro Eerdmans; Gerrit-Anne van Es; Bernhard Meier; Peter Jüni Journal: Lancet Date: 2008-08-31 Impact factor: 79.321
Authors: Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani Journal: J Am Coll Cardiol Date: 2006-05-05 Impact factor: 24.094
Authors: Scot Garg; Patrick Serruys; Yoshinobu Onuma; Cécile Dorange; Susan Veldhof; Karine Miquel-Hébert; Krishnankutty Sudhir; Jean Boland; Kurt Huber; Eulogio Garcia; Jan A M te Riele Journal: JACC Cardiovasc Interv Date: 2009-12 Impact factor: 11.195
Authors: Gregg W Stone; Mark Midei; William Newman; Mark Sanz; James B Hermiller; Jerome Williams; Naim Farhat; Ronald Caputo; Nicholas Xenopoulos; Robert Applegate; Paul Gordon; Roseann M White; Krishnankutty Sudhir; Donald E Cutlip; John L Petersen Journal: Circulation Date: 2009-01-26 Impact factor: 29.690
Authors: Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico Journal: N Engl J Med Date: 2002-06-06 Impact factor: 91.245
Authors: Eliano P Navarese; Kenneth Tandjung; Bimmer Claessen; Felicita Andreotti; Mariusz Kowalewski; David E Kandzari; Dean J Kereiakes; Ron Waksman; Laura Mauri; Ian T Meredith; Aloke V Finn; Hyo-Soo Kim; Jacek Kubica; Harry Suryapranata; Toni Mustahsani Aprami; Giuseppe Di Pasquale; Clemens von Birgelen; Elvin Kedhi Journal: BMJ Date: 2013-11-06